Surgical Oncology Insight最新文献

{"title":"Outcomes following diagnostic laparoscopy in patients with peritoneal carcinomatosis deemed ineligible for cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) due to disease burden","authors":"Paula Marincola Smith ,&nbsp;Ashlee Seldomridge ,&nbsp;Yi-Ju Chiang ,&nbsp;Michael G. White ,&nbsp;Yun Song ,&nbsp;Christopher Scally ,&nbsp;Paul F. Mansfield ,&nbsp;Keith F. Fournier ,&nbsp;Beth A. Helmink","doi":"10.1016/j.soi.2025.100150","DOIUrl":"10.1016/j.soi.2025.100150","url":null,"abstract":"<div><h3>Introduction</h3><div>While cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) can improve overall survival (OS) for patients with peritoneal carcinomatosis from appendiceal or colorectal cancer, some patients are ineligible for CRS/HIPEC due to disease burden. This paper characterizes outcomes for patients who are evaluated by diagnostic laparoscopy (DL) and deemed ineligible for CRS/HIPEC.</div></div><div><h3>Methods</h3><div>Medical records were retrospectively reviewed for patients who underwent DL and deemed ineligible for CRS/HIPEC (1/1/2009–1/1/2024). Date of death was confirmed using public obituaries. Treatment course/causes of death are summarized by descriptive statistics and OS by Kaplan-Meier analysis.</div></div><div><h3>Results</h3><div>124 patients were included. Median Peritoneal Cancer Index (PCI) score was 25. Median follow-up was 1.14 and median OS 1.29 years. 58 (46.8 %) died of their malignancy, 42 (33.9 %) died of unknown cause, and 24 (19.4 %) were alive at last follow-up. The most common causes of death were bowel obstruction (29, 23.4 %), multifactorial/failure to thrive (21, 16.9 %), and malignant ascites (15, 12.1 %). Patients who underwent some form of additional therapy after DL (1.43 versus 0.48 years, p &lt; 0.001) or who enrolled in a clinical trial (1.91 versus 1.21 years, p = 0.030) had prolonged OS.</div></div><div><h3>Conclusions</h3><div>OS for patients with peritoneal carcinomatosis from appendiceal or colorectal cancer who are deemed ineligible for CRS/HIPEC after DL is 1.29 years without significant variation by primary pathology, PCI, peritoneal cytology, or presence of hematogenous metastases. Patients who get some form of additional therapy following their DL have prolonged OS. The most common causes of death are bowel obstruction, failure to thrive, and malignant ascites.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 2","pages":"Article 100150"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144089494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of a technology enhanced breast multidisciplinary cancer conference","authors":"Quratulain Sabih ,&nbsp;Opuruiche Ibekwe ,&nbsp;Carmelo Gaudioso ,&nbsp;Kristopher M. Attwood ,&nbsp;Ellis G. Levine ,&nbsp;Stephen B. Edge ,&nbsp;Chukwumere E. Nwogu","doi":"10.1016/j.soi.2025.100135","DOIUrl":"10.1016/j.soi.2025.100135","url":null,"abstract":"<div><h3>Background</h3><div>Multidisciplinary cancer conferences (MCCs) are the standard approach for managing complex breast cases and technology can facilitate these meetings. The objectives of this study were to assess the impact of technology on quality of patient information, case deliberation, and various outcome measures.</div></div><div><h3>Methods</h3><div>We conducted a prospective study from September 2020 to February 2022, before and after implementation of a digital platform for tumor boards. We collected observational and survey data to assess its impact on quality of breast MCC case presentation and discussion. We also reviewed medical records to compare outcomes including rate of change in care plans, compliance of care plans with national guidelines, concordance of treatment received with MCC recommendations and time from MCC presentation to treatment. Comparisons were made using the Mann-Whitney U and Fisher’s exact tests.</div></div><div><h3>Results</h3><div>There were 39 pre- and 47 post-digital platform patient cases. We found that implementation of technology led to an improvement in the quality of the MCCs (median composite scores: 56.9 vs 68.4; p &lt; 0.001). Specific components significantly improved included case history, reason for presentation, radiology and pathology presentations, and medical oncology contribution to case discussions (mean scores: 3.4 vs 3.9, 3.3 vs 3.9, 2.7 vs 4.1, 3.1 vs 4.2; (p &lt; 0.001), &amp; 3.7 vs 4.1; p = 0.05). There was also an improvement in the frequency of arrival at consensus (71.8 % vs 95.7 %; p &lt; 0.012).</div></div><div><h3>Conclusion</h3><div>A tumor board digital platform was shown to improve the quality of presented patient information, physician engagement, and arrival at consensus at multidisciplinary breast cancer conferences.</div></div><div><h3>Synopsis</h3><div>Multidisciplinary cancer conferences (MCCs) play an important role in breast cancer management. We evaluated the impact of a tumor board-specific technology on the quality of breast MCCs and subsequent care. We found that technology improved the quality of information presented and physician engagement.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 2","pages":"Article 100135"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143739314","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From genes to glands: The genetic framework of parathyroid syndromes","authors":"Niranjna Swaminathan,&nbsp;Julia Adriana Kasmirski,&nbsp;Andrea Gillis,&nbsp;Brenessa Lindeman,&nbsp;Sophie Dream,&nbsp;Herbert Chen","doi":"10.1016/j.soi.2025.100143","DOIUrl":"10.1016/j.soi.2025.100143","url":null,"abstract":"<div><div>Primary and secondary disorders of parathyroid hormone (PTH) secretion including primary hyperparathyroidism (PHPT) and hypoparathyroidism can result from both sporadic and hereditary causes. Advances in molecular genetics have expanded our understanding of the genetic syndromes underlying these disorders. This review aims to summarize the genetic landscape of hereditary parathyroid disorders, highlighting their molecular mechanisms, clinical presentations, diagnostic challenges, and management implications. We synthesized evidence from published literature and genetic testing guidelines issued by major endocrine societies. Specific focus was given to syndromes such as Multiple Endocrine Neoplasia, Hyperparathyroidism-Jaw Tumor (HPT-JT), Familial Isolated Hyperparathyroidism (FIHP), and Autosomal Dominant Hypocalcemia (ADH), among others. While 95 % of PHPT cases are sporadic, a small but clinically significant proportion is linked to germline mutations in genes such as MEN1, RET, CDC73, and CASR. Hypoparathyroid syndromes, though less common, are genetically diverse, involving genes related to parathyroid development, hormone secretion, and calcium-sensing. Current guidelines recommend genetic testing based on early age of onset, multiglandular disease, family history, and associated tumors. As genetic testing becomes more accessible, a precision medicine approach incorporating molecular diagnostics and counseling will play a central role in optimizing patient outcomes.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 2","pages":"Article 100143"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143924575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Single versus multiagent chemotherapy for ampullary carcinoma: A propensity matched multivariate analysis of the NCDB","authors":"Ethan A. Warshowsky ,&nbsp;Dorothy Wakefield ,&nbsp;Ryan Z. Swan ,&nbsp;Michael Minarich","doi":"10.1016/j.soi.2025.100149","DOIUrl":"10.1016/j.soi.2025.100149","url":null,"abstract":"<div><h3>Introduction</h3><div>Pancreatoduodenectomy remains the standard of care for ampullary carcinoma, however the role of adjuvant chemotherapy remains unclear. We investigated the survival benefits of single vs. multi-agent chemotherapy regimens.</div></div><div><h3>Methods</h3><div>The National Cancer Database (NCDB) was queried to identify patients ≥ 18 years old diagnosed with stage II or III carcinoma of the ampulla of Vater between years 2013–2020. Multi-agent usage increased dramatically in 2017, so we categorized by years 2013–2016 vs. 2017–2020. Propensity score matching was performed separately for stage II and III disease using age, race, number of comorbidities and year. Kaplan-Meier (K-M) analysis compared overall survival by single vs. multi-agent chemotherapy for 2013–2016 and 2017–2020. Cox regression analysis examined differences by number of agents while controlling for age, race, number of comorbidities, and year.</div></div><div><h3>Results</h3><div>1207 patients were included in the propensity-matched cohort: 477 who received single vs. 730 who received multi-agent chemotherapy. K-M analyses demonstrated that for 2013–2016, multi-agent therapy showed a significantly longer average survival for both stage II (55.99 vs. 51.43 months) and III (55.90 vs. 50.78 months) disease (p &lt; 0.01). Follow up for the 2017 – 2020 cohort was inadequate for accurate survival reporting. Upon multivariate analysis, a significant advantage in survival with multi-agent chemotherapy was maintained for stage II (HR: 1.44, 95 % CI: 1.14–1.82, p &lt; 0.01) and stage III (HR: 1.41, 95 % CI: 1.09–1.83<strong>,</strong> p = 0.01) disease.</div></div><div><h3>Conclusion</h3><div>For resected, locally advanced ampullary cancer, multi-agent chemotherapy was found to have a significant improvement in overall survival compared to single agent chemotherapy for stage II and III disease.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 2","pages":"Article 100149"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144070614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The evolving treatment for early-stage lung cancer: Immunotherapy","authors":"Erin A. Gillaspie","doi":"10.1016/j.soi.2025.100128","DOIUrl":"10.1016/j.soi.2025.100128","url":null,"abstract":"<div><div>This review article is about the development and use of immunotherapy in the evolving treatment for early-stage lung cancer, which has profoundly altered the treatment landscape. As described in this article, early trial efforts and approvals concentrated on agents for use in the adjuvant phase of treatment and then moved to the neoadjuvant setting. Seminal trials and results are described.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 2","pages":"Article 100128"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144106710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multidisciplinary management of nonmetastatic locally advanced prostate cancer (T3-4N0M0)","authors":"Marcelo P. Bigarella ,&nbsp;John M. Floberg ,&nbsp;David Jarrard","doi":"10.1016/j.soi.2025.100137","DOIUrl":"10.1016/j.soi.2025.100137","url":null,"abstract":"<div><h3>Purpose of review</h3><div>In this review, the current literature available to patients and providers on the multidisciplinary management of nonmetastatic locally advanced prostate cancer (T3-T4N0M0) was reviewed. Topics include the definition of the disease, the distinction between nonmetastatic locally advanced prostate cancer and locally advanced prostate cancer defined by the EUA and high-risk prostate cancer by NCCN and AUA guidelines, the role of radiation therapy in addition to androgen deprivation therapy, the current role of surgery and lypmh node dissectionthe difference between adjuvant vs. salvage treatment for such patients. Although there are multiple curative treatment approaches for locally advanced prostate cancer, no consensus regarding the optimal treatment option exists.</div></div><div><h3>Recent findings</h3><div>Historically, the use of androgen deprivation therapy (ADT) and external beam radiotherapy (EBRT) has been used in locally advanced prostate cancer¹. More recently, retrospective observational data showed equivalent results for patients undergoing primary radical prostatectomy with radiation therapy reserved as an adjuvant or salvage treatment as needed, and better outcomes were seen after advances in patient selection which include improvements in staging imaging with mpMRI and PSMA PET^2,3. Adjuvant radiation based on adverse features on pathology has also come into dispute, with early salvage showing non-inferior oncological outcomes and a more favorable toxicity profile.</div></div><div><h3>Summary</h3><div>Until high-level evidence evaluating surgery versus EBRT plus androgen deprivation therapy (ADT) for locally advanced disease is available as a result of the ongoing trial SPCG-15, options for patients with locally advanced prostate cancer include local radiotherapy in combination with androgen deprivation therapy (level I evidence) and radical prostatectomy with pelvic lymph node dissection for well-selected patients. Early salvage radiotherapy is non-inferior to adjuvant radiation.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 2","pages":"Article 100137"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143725024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intraoperative fluid management in patients undergoing CRS-HIPEC, a retrospective study","authors":"Mark Antkowiak ,&nbsp;Megan Meyer ,&nbsp;Gerard Manecke ,&nbsp;Harpreet Gill ,&nbsp;Andrew Lowy ,&nbsp;Jula Veerapong ,&nbsp;Joel Baumgartner","doi":"10.1016/j.soi.2025.100133","DOIUrl":"10.1016/j.soi.2025.100133","url":null,"abstract":"<div><h3>Introduction</h3><div>CRS-HIPEC requires complex perioperative fluid management due to the associated physiologic disturbances. Several studies have postulated that restrictive intraoperative fluid management is associated with decreased postoperative morbidity. Evidence-based guidelines for fluid management in CRS-HIPEC have not yet been established and proper management of intraoperative fluid therapy remains controversial.</div></div><div><h3>Methods</h3><div>We performed a retrospective cohort study on patients undergoing CRS-HIPEC at a high-volume center with a total of 620 procedures performed from March 2011 to December 2020. Patients were split into restrictive and liberal fluid administration groups by intraoperative fluid administration rate and the primary outcome of comprehensive complication index (CCI) was compared between groups. Univariable and multivariable regression analyses were performed to evaluate the association of perioperative factors on outcomes and to control for confounding factors.</div></div><div><h3>Results</h3><div>Of 620 total procedures performed, 58 were excluded due to missing data. In the remaining procedures, patients had a mean age of 55 years (range 20, 86), mean peritoneal carcinomatosis index of 13.8 (CI 13.1, 14.5), and mean intraoperative fluid administration rate of 12.1 mL/kg/hr (CI 11.7, 12.5). The mean CCI for the restrictive fluid management group was 12.5 (CI 10.8, 14.3) and for the liberal group was 14.2 (CI 12.5, 16.1) [p = 0.18]. Univariable and multivariable regression analyses showed no association between intraoperative fluid rate and CCI (univariable coefficient = 0.17, p = 0.19; multivariable coefficient = 0.14, p = 0.52).</div></div><div><h3>Conclusions</h3><div>Restrictive intraoperative fluid management during CRS-HIPEC is not associated with decreased postoperative morbidity as measured by CCI.</div></div><div><h3>Synopsis</h3><div>This is the largest study to date evaluating the association of intraoperative fluid administration with postoperative complications in patients undergoing CRS-HIPEC. We find that fluid administration strategy is not associated with postoperative complications. Rather than restrictive management, our study suggests that fluid administration should be tailored to individual patient needs.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 2","pages":"Article 100133"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143621289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DOTATATE PET CT tumor volume as a predictor of surgical outcome in patients with metastatic gastroenteropancreatic neuroendocrine tumors","authors":"Sara Abou Azar ,&nbsp;Joseph Tobias ,&nbsp;Nicholas Feinberg ,&nbsp;Daniel Appelbaum ,&nbsp;Yonglin Pu ,&nbsp;Frances Lee ,&nbsp;Jason L. Schwarz ,&nbsp;Jelani Williams ,&nbsp;Rachel Nordgren ,&nbsp;J. Michael Millis ,&nbsp;Chih-Yi “Andy” Liao ,&nbsp;Xavier M. Keutgen","doi":"10.1016/j.soi.2025.100141","DOIUrl":"10.1016/j.soi.2025.100141","url":null,"abstract":"<div><h3>Background</h3><div>Surgical debulking for metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) is associated with increased progression-free survival (PFS) and overall survival (OS) in retrospective studies. It remains unclear, however, which patients benefit most from surgery. DOTATATE PET/CT tumor volume (TV) in metastatic GEP-NETs has been shown to correlate with PFS and OS. Herein, we investigate how TV impacts outcomes in patients undergoing surgical debulking for GEP-NETs.</div></div><div><h3>Methods</h3><div>A retrospective chart review was conducted of patients with pancreatic and small bowel NET (PNET/SBNET) who underwent surgical debulking at our institution from 2019 to 2022. All patients had an estimated liver debulking threshold of &gt; 90 % and only patients with preoperative ⁶⁸Ga or ⁶⁴Cu-DOTATATE PET/CT were included. TV was obtained using the MIM Encore workstation.</div></div><div><h3>Results</h3><div>71 patients with metastatic GEP-NETs (35 % PNET and 65 % SBNET) underwent liver debulking with 19 synchronous primary tumor resections. 42 patients had symptomatic disease. Patients were divided into 4 TV quartiles, ranging from 8.46 to 2000 mL. On cox proportional hazards modeling, tumor volume stratified by quartiles was not significantly associated with longer PFS (p = 0.250) over a median follow-up of 13 months (7−23). However, there was an increased risk for Clavien-Dindo Grade III and IV complications with higher TV quartiles (p = 0.008). SBNETs with carcinoid syndrome (p = 0.047) and those with more lesions debulked (p = 0.025) were more likely to have improvement in postoperative symptoms.</div></div><div><h3>Conclusion</h3><div>Patients with larger tumor burden on preoperative DOTATATE PET/CT should not be excluded from surgical intervention but may need to be counseled on higher risks of operative complications.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 2","pages":"Article 100141"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143790977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver resection that is less extensive than segmentectomy for hepatocellular carcinoma focused on the fourth branch of the portal vein","authors":"Shingo Shimada ,&nbsp;Hiroyuki Takahashi,&nbsp;Shoichiro Mizukami,&nbsp;Yuki Adachi,&nbsp;Koji Imai,&nbsp;Hideki Yokoo","doi":"10.1016/j.soi.2025.100140","DOIUrl":"10.1016/j.soi.2025.100140","url":null,"abstract":"<div><h3>Background</h3><div>The optimal location of the portal branch to be removed by liver resection that is less than a segmentectomy for patients with hepatocellular carcinoma (HCC) is elusive. This study examines the impact of removing the fourth branch on postsurgical outcomes.</div></div><div><h3>Methods</h3><div>HCC patients who underwent liver resection less extensive than segmentectomy (2015–2022) were included. The impact of removing the fourth branch of the tumor-bearing portal vein (PVR) on recurrence was evaluated using Gray and Fine-Gray methods, adjusted for confounding factors. Overall survival was assessed via the Kaplan-Meier method and log-rank test.</div></div><div><h3>Results</h3><div>Of the 89 patients eligible for this study, 47 were in the PVR group, and 42 were in the non-PVR group. The PVR group had a significantly lower median level of total bilirubin; however, other covariates related to liver function were comparable to those in the non-PVR group. Additionally, oncological and operative covariates were comparable between the two groups. The 1-, 3-, and 5-year cumulative incidences of recurrence were significantly lower in the PVR group than in the non-PVR group (10.9 %, 34.1 %, and 43.2 % vs. 21.6 %, 59.1 %, and 71.1 %, respectively; P = 0.01). The overall survival rates were comparable between the groups. Bivariable analysis was adjusted for recurrence using significant covariates identified by the univariable analysis and revealed that non-PVR surgery was associated with a significantly greater risk of HCC recurrence with any combination of other significant factors.</div></div><div><h3>Conclusions</h3><div>The risk of short-term intrahepatic recurrence may be reduced by liver resection via removal of the fourth branch of the portal vein.</div></div>","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 2","pages":"Article 100140"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143783068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitomycin C in HIPEC: A proposal to use abdominal cavity volume for drug dosage","authors":"George I. Salti ,&nbsp;Isabella D. Salti ,&nbsp;Aslam Ejaz ,&nbsp;Shankar Logarajah","doi":"10.1016/j.soi.2025.100142","DOIUrl":"10.1016/j.soi.2025.100142","url":null,"abstract":"","PeriodicalId":101191,"journal":{"name":"Surgical Oncology Insight","volume":"2 2","pages":"Article 100142"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143923229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}